Suppr超能文献

瘤内注射溶瘤病毒H101联合卡培他滨治疗巨大结直肠癌淋巴结转移获病理完全缓解1例报告

A Case Report of Pathologically Complete Response of a Huge Lymph Node Metastasis of Colorectal Cancer After Treatment with Intratumoral Oncolytic Virus H101 and Capecitabine.

作者信息

Wang Yaqin, Wang Tianxiao, Zhang Yuewei

机构信息

Hepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, 102218, People's Republic of China.

出版信息

Immunotargets Ther. 2024 Jul 4;13:343-348. doi: 10.2147/ITT.S470018. eCollection 2024.

Abstract

Unresectable recurrent lymph node metastasis of colorectal cancer (CRC) is considered as an incurable disease clinically and has a very poor prognosis. Here, we report a male KRAS wild-type CRC case with a huge abdominal lymph node metastasis (12 cm in diameter) after CRC surgery. After three intratumoral injections of oncolytic virus (H101) combined with four cycles of low-dose oral capecitabine, the size of the metastatic lymph node shrank remarkably in response to the anticancer drug and a complete response (CR) was achieved with progression-free survival (PFS) of 19 months. The main adverse reaction was mild fever, which was relieved after physical cooling. The patient is in a general good condition now without any relapse of abdominal lymph node for over a year. On this basis, we propose that the combination therapy of oncolytic virus and capecitabine could be a promising clinical therapeutic strategy for unresectable recurrent lymph node metastasis in CRC patients.

摘要

结直肠癌(CRC)不可切除的复发性淋巴结转移在临床上被视为不治之症,预后非常差。在此,我们报告1例男性KRAS野生型CRC病例,该患者在CRC手术后出现巨大腹部淋巴结转移(直径12厘米)。在瘤内注射3次溶瘤病毒(H101)并联合4个周期的低剂量口服卡培他滨后,转移性淋巴结的大小因抗癌药物治疗而显著缩小,并实现了完全缓解(CR),无进展生存期(PFS)为19个月。主要不良反应为轻度发热,经物理降温后缓解。患者目前总体状况良好,腹部淋巴结在一年多的时间里未出现任何复发。在此基础上,我们提出溶瘤病毒与卡培他滨联合治疗可能是CRC患者不可切除复发性淋巴结转移一种有前景的临床治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7832/11230130/8b99278de560/ITT-13-343-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验